Search bioRxiv⌕ Search

Biology subjects

Li, Q.-X.

Publications and source records attributed to Li, Q.-X..

2 recordsLinked to original sources

A mouse model of hemochromatosis-related mutations with brain iron dyshomeostasis exhibits loss of tyrosine hydroxylase expression in dopaminergic neurons and motor control impairment relevant to Parkinson's disease

UK Biobank studies show Parkinsons disease risk is almost doubled in men homozygous for the homeostatic iron regulator gene HFE p.C282Y polymorphism, associated with the common genetic iron disorder hemochromatosis. Whether this relationship is causal or spurious is unknown. We previously reported a novel Hfe-/-xTfr2mut mouse model of hemochromatosis with elevated brain iron ([~]1.5-1.8x). We now show these mice have reduced substantia nigra tyrosine hydroxylase expression at 3 months and 9 months age, sometimes exhibit severe hindlimb clasping by 7-8 months, have impaired rotarod and balance beam performance at 9 months and are untestable on the pole test. These parkinsonian features place the model at the forefront of genetic mouse models of PD, which generally do not show both TH loss and motor impairment. This confirms hemochromatosis-related mutations can cause parkinsonian features, substantiating causality of epidemiological relationships. Despite total brain iron elevation, neuronal iron remains low in Hfe-/-xTfr2mut mice, consistent with hemochromatosis-related mutations disrupting the normal, iron-responsive regulation of the neuronal iron exporter ferroportin by hepcidin. Parkinsonian features may reflect reduced mitochondrial respiratory complex (MRC) activity due to functional neuronal iron depletion. This may be exacerbated by indiscriminate chelation and could instead respond to drugs targeting the hepcidin-ferroportin axis or MRC activity. This new model of chronic parkinsonism that increases with age provides unprecedented insights into the complex relationships of brain iron regulation and movement impairment. Since parkinsonism of diverse etiologies can exhibit iron dysregulation, the model may facilitate pre-clinical to end-stage studies relevant to both sporadic and genetic PD.

neuroscience↗

The design, analysis and application of mouse clinical trials in oncology drug development

Mouse clinical trials (MCTs) are becoming widely used in pre-clinical oncology drug development. In this study, we provide some general guidelines on the design, analysis and application of MCTs. We first established empirical quantitative relationships between mouse number and measurement accuracy for both categorical and continuous efficacy endpoints, and showed that more mice are needed to achieve given accuracy for syngeneic models than for PDXs and CDXs. There is considerable disagreement between categorical methods on calling drug responses as objective response, indicating limitations of such approaches. We then introduced linear mixed models, or LMMs, to describe MCTs as clustered longitudinal studies, which explicitly model growth and drug response heterogeneities across mouse models and among mice within a mouse model. Several case studies were used to demonstrate the advantages of LMMs in discovering biomarkers and exploring a drugs mechanism of action. We also introduced the additive frailty models to perform survival analysis on MCTs, which more accurately estimate hazard ratios by modeling the clustered population structures in MCTs. We performed computational simulations for LMMs and frailty models to generate statistical power curves, and showed that statistical power is close for designs with similar total number of mice at given drug efficacy. Finally, we explained how MCTs can explain discrepant results in clinical trials, hence, MCTs are more than preclinical versions of clinical trials but possess their unique values. Results in the report will make MCTs a better tool for oncology drug development.

cancer biology↗